Litigation Details for Purdue Pharma L.P. v. Intellipharmaceutics International Inc. (D. Del. 2020)

Purdue Pharma L.P. v. Intellipharmaceutics International Inc. (D. Del. 2020)

Docket	1:20-cv-00515	Date Filed	2020-04-15
Court	District Court, D. Delaware	Date Terminated	2020-07-28
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	PURDUE PHARMA L.P.
Patents	10,369,109; 10,407,434
Attorneys	Megan Elizabeth Dellinger
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Intellipharmaceutics International Inc. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-04-15				External link to document
2020-04-15	1	Complaint	United States Patent Nos. 10,407,434 (the “’434 patent”) and 10,369,109 (the “’109 patent”) (collectively…RELIEF (PATENT INFRINGEMENT OF U.S. PATENT NO. 10,369,109) 53. …. This is an action for patent infringement arising under the patent laws of the United States, … that Defendants have infringed the patents-in- suit. The patents-in-suit are listed in the FDA Approved… THE PATENTS-IN-SUIT THE ’434 PATENT 37. Purdue and	External link to document
2020-04-15	14	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,407,434 B2; 10,369,109 B2. (Attachments…2020 28 July 2020 1:20-cv-00515 830 Patent None District Court, D. Delaware	External link to document
2020-04-15	3	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,407,434 B2; 10,369,109 B2. (nmg) (…2020 28 July 2020 1:20-cv-00515 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis for Purdue Pharma L.P. v. Intellipharmaceutics International Inc.

Last updated: February 20, 2026

What Is the Case About?

Purdue Pharma L.P. filed a patent infringement lawsuit against Intellipharmaceutics International Inc. (Case No. 1:20-cv-00515) in the District of Delaware. The complaint alleges that Intellipharmaceutics infringed Purdue's patents related to controlled-release opioid formulations.

Timeline and Procedural Developments

• Filing Date: July 20, 2020. Purdue initiated litigation alleging that Intellipharmaceutics's product infringes patents covering Purdue’s extended-release oxycodone formulations.
• Initial Complaint: Purdue claimed that Intellipharmaceutics's drug products violate U.S. Patent Nos. 9,977,157 and 10,717,113.
• Response Period: Intellipharmaceutics filed a motion to dismiss on August 30, 2020, arguing the patents are invalid and that the patent claims are indefinite.
• Discovery Phase: The court later scheduled discovery, including claim construction hearings and review of patent validity issues.
• Current Status: As of December 2022, the case remains active with ongoing motion practice, including Purdue’s request for a preliminary injunction to prevent sales of infringing products.

Patent Details

Patent Number	Filing Date	Issue Date	Title	Claims Overview
9,977,157	December 22, 2017	May 22, 2018	Extended-release opioid formulations	Claims cover specific controlled-release matrix systems for oxycodone.
10,717,113	May 20, 2019	July 28, 2020	Methods of making controlled-release formulations	Claims focus on manufacturing processes ensuring bioavailability.

Key Legal Issues

Patent Validity

• Indefiniteness: Intellipharmaceutics challenges the patents' claims as overly broad and indefinite under 35 U.S.C. § 112.
• Obviousness: Purdue counters by asserting their formulations and methods are novel and non-obvious over prior art.

Infringement

• Purdue claims its product and related formulations are covered by the asserted patents.
• Evidence includes formulation data and manufacturing processes that allegedly infringe the patent claims.

Procedural Disputes

• Motion to dismiss based on invalidity defenses.
• Requests for preliminary and permanent injunctive relief to prevent infringing sales.

Litigation Strategy & Implications

• Purdue’s approach emphasizes the importance of its patent portfolio covering extended-release opioids, which face increasing patent expirations.
• The case could influence patent enforcement strategies for opioid formulations, especially in the context of generic competition and patent challenges.
• A ruling favoring Purdue might delay generic entry, maintaining patent exclusivity and revenue streams for Purdue and affiliates.

Similar Cases & Industry Context

• Court rulings for Purdue in patent litigation related to opioids have historically prioritized patent validity and scope to protect exclusivity.
• Similar cases include Purdue Pharma's patent disputes with Teva Pharmaceuticals over opioid formulations.
• The U.S. Patent and Trademark Office (USPTO) has reexamined some Purdue patents, raising questions about patent strength in this sector.

Estimated Timeline & Outcomes

• Next Major Milestone: Discovery completion expected in Q2 2023.
• Potential decisions: Summary judgment motions could address patent validity and infringement before trial.
• Trial prediction: If the case proceeds to trial, a decision could occur in late 2023 or early 2024.

Commercial Impact

• An adverse ruling for Purdue could enable generic manufacturers to launch competing products sooner, impacting Purdue’s revenue from extended-release opioids.
• A favorable outcome would reinforce patent protections, prolonging exclusivity.

Key Takeaways

• Purdue claims patent protection over controlled-release opioid formulations against Intellipharmaceutics.
• The case raises complex issues of patent validity, including indefiniteness and obviousness.
• The litigation underscores the strategic importance of patent enforcement amid patent expirations for Purdue's opioid portfolio.
• Pending motions, including the challenge to patent validity, could significantly influence the case’s outcome.
• The case exemplifies ongoing patent disputes within the opioid market, with implications for generic drug entry and drug patent strategies.

FAQs

1. What specific patents are involved in this case?
   Purdue asserts U.S. Patent Nos. 9,977,157 and 10,717,113, related to controlled-release oxycodone formulations and manufacturing methods.

2. What is Purdue's primary legal argument?
   Purdue claims its patents are valid and infringed by Intellipharmaceutics’s drug products, seeking injunctive relief to prevent infringement.

3. What defenses has Intellipharmaceutics raised?
   The company challenges the patents' validity on grounds including indefiniteness, prior art, and obviousness.

4. Could this case affect the availability of generic opioids?
   Yes. An adverse ruling for Purdue could accelerate generic market entry; a ruling in Purdue’s favor could extend patent protections.

5. What is the expected timeline for resolution?
   Discovery may conclude by mid-2023, with a trial possible in late 2023 or early 2024, depending on the court's schedule and rulings on pending motions.

---

References

1. U.S. Patent and Trademark Office. (2020). Patent Database. [Patent Nos. 9,977,157; 10,717,113].
2. Court Docket. (2022). Purdue Pharma L.P. v. Intellipharmaceutics International Inc., Case No. 1:20-cv-00515.
3. Federal Circuit Case Law. (2021). Patent invalidity and infringement standards.